Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity

Why It Matters

The convergence of regulatory shifts, geopolitical realignment, and manufacturing challenges will dictate which therapies reach patients and where capital flows, reshaping the future of advanced therapeutics.

Key Takeaways

• FDA plausible mechanism pathway aims to speed CGT approvals
• US cuts $500M mRNA projects; Moderna halts late-stage trials
• China biotech pipeline rivals US after eightfold growth
• Manufacturing consistency critical for scaling AAV gene therapies
• Funding gap persists for early-stage CGT startups despite big‑pharma deals

Pulse Analysis

Advanced Therapies Week 2026 arrives at a crossroads for cell and gene therapy, where scientific breakthroughs meet geopolitical turbulence. The United States is grappling with policy reversals, exemplified by the Health Secretary’s termination of $500 million in mRNA vaccine projects and Moderna’s abrupt trial halt. Simultaneously, China’s biotech sector has surged, delivering an eightfold increase in novel candidates and positioning itself as a near‑equal rival to U.S. pipelines. These dynamics force investors and developers to reassess market strategies amid shifting regulatory and funding landscapes.

Regulatory evolution is a double‑edged sword for the CGT arena. The FDA’s new plausible‑mechanism pathway, highlighted in the KJ Muldoon CRISPR case, could streamline approvals for rare‑disease therapies, yet recent surprise rejections of UniQure’s AMT‑130, Capricor’s deramiocel, and Ultragenyx’s UX111 reveal lingering uncertainty. Manufacturing reliability, especially for AAV vectors, is now as crucial as scientific innovation, with industry leaders emphasizing consistent cGMP production to sustain late‑stage and commercial programs. This tension between accelerated pathways and stringent evidence requirements will shape the next wave of gene‑editing platforms.

Capital flows remain uneven. While Big‑Pharma firms secure pricing accords with the White House, early‑stage CGT startups continue to face a funding drought that only eased in late 2025. The Investment Summit at ATW will spotlight data‑driven outlooks and define what makes a biotech fundable in 2026. Notably, the conference dedicates sessions to women’s health and women‑led founders, signaling a broader push for diversity in biotech leadership. Stakeholders must navigate these intertwined scientific, regulatory, and financial currents to capture the market’s next growth frontier.